Last week, the Patent Trial and Appeal Board issued a final written decision in IPR2016-01771, filed by Hospira to challenge U.S. Pat. No. 7,622,115. The Board invalidated all 5 claims of the ’115 patent, which is directed to methods for treating cancer in a patient comprising administering an effective amount of bevacizumab and assessing the patient for gastrointestinal perforation during treatment with bevacizumab. The ’115 patent is also at issue in pending district court litigation between Genentech and Amgen regarding Amgen’s bevacizumab biosimilar, MVASI®.
Stay tuned to Big Molecule Watch for more IPR updates.